ES2074138T3 - Metodo para utilizar (2-imidazolin-2-ilamino)-quinoxalinas para reducir o mantener la presion intraocular. - Google Patents
Metodo para utilizar (2-imidazolin-2-ilamino)-quinoxalinas para reducir o mantener la presion intraocular.Info
- Publication number
- ES2074138T3 ES2074138T3 ES90311755T ES90311755T ES2074138T3 ES 2074138 T3 ES2074138 T3 ES 2074138T3 ES 90311755 T ES90311755 T ES 90311755T ES 90311755 T ES90311755 T ES 90311755T ES 2074138 T3 ES2074138 T3 ES 2074138T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- imidazolin
- hydrogen
- positions
- intraocular pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA INVENCION DESCRIBE LA UTILIZACION DE UN COMPUESTO DE LA FORMULA (1) Y SUS SALES DE ADICION ACIDA, ACEPTABLES FARMACEUTICAMENTE, Y SUS MEZCLAS DONDE; R SUB 1 ES HIDROGENO R SUB 2 ES C SUB 1-4 ALQUILO O C SUB 1-4 ALCOXI, EL GRUPO 2-IMIDAZOLINO(2)ILAMINO ESTA EN UNA DE LAS POSICIONES 5-, 6-, 7-, U 8 UCLEO QUINOXALINO, Y R SUB 3 R SUB 4 Y R SUB 5 ESTAN CADA UNA LOCALIZADAS EN UNA DE LAS POSICIONES RESTANTES 5-, 6-, 7DEL NUCLEO QUINOXALINO Y SON SELECCIONADAS INDEPENDIENTEMENTE DE CI, B SUB R, HIDROGENO Y C SUB 1-3 ALQUILO, PARA LA PRODUCCION DE UN MEDICAMENTO PARA REDUCIR O MANTENER LA PRESION INTRAOCULAR EN EL OJO DE UN MANIFERO, POR EJEMPLO EN UN OJO CON GLAUCOMA. TAMBIEN, SE DESCRIBE EL USO DE UN COMPUESTO DE LA FORMULA (II) Y SUS SALES DE ADICION ACIDA, ACEPTABLES FARMACEUTICAMENTE, ASI COMO SUS MEZCLAS, DONDE; R SUB 1 Y R SUB 2 SON SELECCIONADAS INDEPENDIENTEMENTE DE HIDROGENO, C SUB 1-4 ALQUILO Y C SUB 1-4 ALCOXI; EL GRUPO 2-IMIDAZOLINO(2)ILAMINO ESTA EN CUALQUIERA DE LAS POSICIONES 6-, 7 R SUB 3 ES HIDROGENO O C SUB 1-3 ALQUILO, Y R SUB 4 Y R SUB 5 ESTAN CADA UNA LOCALIZADAS EN LAS RESTANTES POSICIONES 6-, 7U 8 R H Y RADICALES ALQUILOS, C SUB 1DE UN MEDICAMENTO PARA REDUCIR O MANTENER LA PRESION INTRAOCULAR EN UN OJO DE MANIFERO, POR EJEMPLO EN UN OJO AFECTADO DE GLAUCOMA. LA INVENCION TAMBIEN DESCRIBE COMPOSICIONES OFTALMICAS DE USO TOPICO QUE COMPRENDEN UN COMPUESTO DE LA FORMULA (I) O (II) Y UN CONDUCTOR ACEPTABLE OFTALMICAMENTE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/429,835 US5021416A (en) | 1989-10-31 | 1989-10-31 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2074138T3 true ES2074138T3 (es) | 1995-09-01 |
Family
ID=23704912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES90311755T Expired - Lifetime ES2074138T3 (es) | 1989-10-31 | 1990-10-26 | Metodo para utilizar (2-imidazolin-2-ilamino)-quinoxalinas para reducir o mantener la presion intraocular. |
Country Status (18)
Country | Link |
---|---|
US (1) | US5021416A (es) |
EP (1) | EP0426390B1 (es) |
JP (1) | JP2999240B2 (es) |
KR (1) | KR910007530A (es) |
AT (1) | ATE122233T1 (es) |
AU (1) | AU627626B2 (es) |
CA (1) | CA2025189A1 (es) |
DE (1) | DE69019297T2 (es) |
ES (1) | ES2074138T3 (es) |
FI (1) | FI905369A0 (es) |
HU (1) | HU207946B (es) |
IE (1) | IE68413B1 (es) |
IL (1) | IL96083A (es) |
NZ (1) | NZ235884A (es) |
PH (1) | PH26978A (es) |
RU (1) | RU1829937C (es) |
TW (1) | TW218352B (es) |
ZA (1) | ZA908731B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5112822A (en) * | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5231096A (en) * | 1989-10-12 | 1993-07-27 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5326763A (en) * | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
WO1995010280A1 (en) * | 1993-10-13 | 1995-04-20 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
ATE194771T1 (de) * | 1993-12-17 | 2000-08-15 | Procter & Gamble | 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten |
US5576437A (en) * | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
BR9408335A (pt) * | 1993-12-17 | 1997-08-19 | Procter & Gamble | Composto uso do mesmo e composição farmacêutica |
US5578607A (en) * | 1993-12-17 | 1996-11-26 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US5916900A (en) | 1995-06-29 | 1999-06-29 | The Procter & Gamble Company | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
NZ504707A (en) | 1997-11-24 | 2002-11-26 | Procter & Gamble | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US20050026924A1 (en) * | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
EP1301210A2 (en) | 2000-07-14 | 2003-04-16 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
NZ521185A (en) * | 2000-07-14 | 2005-02-25 | Allergan Inc | Compositions containing alpha-2-adrenergic agonist components |
WO2002089853A2 (en) * | 2001-05-03 | 2002-11-14 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
US20020198210A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Alpha-2-adrenergic agonist/fatty acid compositions |
US20020198209A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
US7030149B2 (en) | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
ATE444732T1 (de) | 2003-08-07 | 2009-10-15 | Allergan Inc | Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung |
WO2008144399A1 (en) * | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS |
US9192571B2 (en) * | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
US7842714B2 (en) * | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US20110003823A1 (en) * | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US20180369240A1 (en) * | 2008-08-01 | 2018-12-27 | Eye Therapies Llc | Preferential Vasoconstriction Compositions and Methods of Use |
US20100202979A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of pulmonary diseases and conditions |
US20100197694A1 (en) * | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
DK2320911T3 (da) * | 2008-08-01 | 2014-11-03 | Eye Therapies Llc | Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
WO2011117377A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
US8916562B2 (en) | 2010-03-26 | 2014-12-23 | Galderma Research & Development Snc | Methods and compositions for safe and effective treatment of telangiectasia |
WO2011127139A2 (en) | 2010-04-07 | 2011-10-13 | Allergan, Inc. | Combinations of preservative compositions for ophthalmic formulations |
JP2013523828A (ja) | 2010-04-07 | 2013-06-17 | アラーガン インコーポレイテッド | 眼科用組成物のための保存剤の組み合わせ |
TR201818754T4 (tr) | 2010-07-29 | 2019-01-21 | Allergan Inc | Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri |
NO2444068T3 (es) | 2010-10-21 | 2014-12-20 | ||
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
JP6339364B2 (ja) * | 2013-12-27 | 2018-06-06 | カズマパートナーズ株式会社 | 無定形ブリモニジン酒石酸塩及びその製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
GB1463520A (en) * | 1974-09-06 | 1977-02-02 | Pfizer Ltd | Process for the production of imidazolines |
US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
-
1989
- 1989-10-31 US US07/429,835 patent/US5021416A/en not_active Expired - Lifetime
-
1990
- 1990-09-12 CA CA002025189A patent/CA2025189A1/en not_active Abandoned
- 1990-09-19 PH PH41224A patent/PH26978A/en unknown
- 1990-10-05 TW TW079108344A patent/TW218352B/zh active
- 1990-10-10 AU AU63966/90A patent/AU627626B2/en not_active Ceased
- 1990-10-15 ZA ZA908731A patent/ZA908731B/xx unknown
- 1990-10-22 IL IL96083A patent/IL96083A/xx not_active IP Right Cessation
- 1990-10-26 ES ES90311755T patent/ES2074138T3/es not_active Expired - Lifetime
- 1990-10-26 AT AT90311755T patent/ATE122233T1/de not_active IP Right Cessation
- 1990-10-26 DE DE69019297T patent/DE69019297T2/de not_active Expired - Fee Related
- 1990-10-26 EP EP90311755A patent/EP0426390B1/en not_active Expired - Lifetime
- 1990-10-30 FI FI905369A patent/FI905369A0/fi not_active Application Discontinuation
- 1990-10-30 IE IE389690A patent/IE68413B1/en not_active IP Right Cessation
- 1990-10-30 HU HU906934A patent/HU207946B/hu not_active IP Right Cessation
- 1990-10-30 NZ NZ235884A patent/NZ235884A/xx unknown
- 1990-10-31 RU SU904831722A patent/RU1829937C/ru active
- 1990-10-31 JP JP2297019A patent/JP2999240B2/ja not_active Expired - Lifetime
- 1990-10-31 KR KR1019900017735A patent/KR910007530A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE69019297D1 (de) | 1995-06-14 |
RU1829937C (ru) | 1993-07-23 |
PH26978A (en) | 1992-12-28 |
FI905369A0 (fi) | 1990-10-30 |
US5021416A (en) | 1991-06-04 |
IL96083A (en) | 1997-06-10 |
JP2999240B2 (ja) | 2000-01-17 |
IE68413B1 (en) | 1996-06-12 |
HUT57045A (en) | 1991-11-28 |
IL96083A0 (en) | 1991-07-18 |
KR910007530A (ko) | 1991-05-30 |
NZ235884A (en) | 1997-08-22 |
ATE122233T1 (de) | 1995-05-15 |
AU627626B2 (en) | 1992-08-27 |
DE69019297T2 (de) | 1995-10-12 |
JPH03153626A (ja) | 1991-07-01 |
IE903896A1 (en) | 1991-05-08 |
HU207946B (en) | 1993-07-28 |
EP0426390B1 (en) | 1995-05-10 |
HU906934D0 (en) | 1991-05-28 |
TW218352B (es) | 1994-01-01 |
EP0426390A3 (en) | 1992-03-04 |
EP0426390A2 (en) | 1991-05-08 |
ZA908731B (en) | 1991-07-31 |
AU6396690A (en) | 1991-05-09 |
CA2025189A1 (en) | 1991-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2074138T3 (es) | Metodo para utilizar (2-imidazolin-2-ilamino)-quinoxalinas para reducir o mantener la presion intraocular. | |
ES2063289T3 (es) | (2-imidazolin-2-ilamino) tetrahidroquinoxalinas y metodos para usarlas. | |
US5075323A (en) | Compounds including omeprazole in the treatment of glaucoma | |
KR940019701A (ko) | N-헤테로아릴-n'-페닐우레아 유도체, 그의 제조방법 및 용도 | |
CA2240136A1 (en) | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives | |
HU9301197D0 (en) | Medical preparatives containing quinoline and quinazoline derivatives as well as new quinoline and quinazoline derivatives | |
DE69312567T2 (de) | 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel | |
ES8506652A1 (es) | Un metodo de preparar dihidrobenzopirrolbenzodiazepinas | |
PT92540A (pt) | Processo para a preparacao de derivados de anfotericina b | |
ES8604167A1 (es) | Un procedimiento para la preparacion de un derivado de acido 2-anilino-1, 6-dihidro-6-oxo-5-pirimidincarboxilico | |
ES2084006T3 (es) | Uso de 2-cicloalquil-amino-oxazolinas para reducir o mantener la presion intraocular. | |
ES8702390A1 (es) | Un procedimiento para la preparacion de nuevos derivados de 1,5-benzotiazepina | |
ATE56713T1 (de) | 1,2,3,4,4a,9b-hexahydro-4aaminoalkyldibenzofurane, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
AU6599186A (en) | N-(6-(4-0-hydrxyphenyl-1,3-dioxan-cis-5-yl)hexenoyl) suphonamide derivatives | |
HU9602534D0 (en) | Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity | |
SE9402596D0 (sv) | Karboximetylidencykloheptimidazolderivat, förfarande för deras framställning och terapeutiska medel innehållande dessa | |
KR930010009A (ko) | 벤조퀴녹살린류 화합물 | |
DE69407227D1 (de) | Die Verwendung von 2-Phenylmethylene-1-3'-(amino)-2-(hydroxy)-propoxy-imino-cyclohexane-Derivaten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 426390 Country of ref document: ES |